Victrex plc (LON:VCT) has been assigned an average recommendation of “Hold” from the eleven research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is GBX 2,261.88 ($29.56).
Several research firms recently commented on VCT. Stifel Nicolaus downgraded shares of Victrex to a “hold” rating and reduced their price target for the company from GBX 2,255 ($29.47) to GBX 2,125 ($27.77) in a research report on Friday. Liberum Capital reiterated a “buy” rating on shares of Victrex in a research report on Thursday, August 22nd. Credit Suisse Group began coverage on shares of Victrex in a research report on Monday, September 2nd. They issued an “outperform” rating and a GBX 2,700 ($35.28) price target for the company. Barclays upgraded shares of Victrex to an “equal weight” rating and set a GBX 2,020 ($26.39) price target for the company in a research report on Wednesday, August 21st. Finally, UBS Group reiterated a “neutral” rating on shares of Victrex in a research report on Friday, July 26th.
VCT stock traded down GBX 4 ($0.05) on Wednesday, hitting GBX 2,158 ($28.20). The company’s stock had a trading volume of 140,085 shares, compared to its average volume of 274,177. The firm has a 50 day moving average of GBX 2,031.12 and a two-hundred day moving average of GBX 2,143.03. Victrex has a 1 year low of GBX 1,813.68 ($23.70) and a 1 year high of GBX 3,400 ($44.43). The stock has a market cap of $1.86 billion and a price-to-earnings ratio of 18.77.
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, ortho, dental, trauma, knee, cardiovascular, and orthopedic applications. It also offers specialist solutions for medical device manufacturers.
See Also: Bond
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.